Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/32005
Full metadata record
DC FieldValueLanguage
dc.contributor.authorQiu, Xun-
dc.contributor.authorXu, Hanzhi-
dc.contributor.authorWang, Kai-
dc.contributor.authorGao, Fengqiang-
dc.contributor.authorXu, Xiao-
dc.contributor.authorHe, Hong-
dc.date2023-
dc.date.accessioned2023-01-24T03:20:01Z-
dc.date.available2023-01-24T03:20:01Z-
dc.date.issued2023-01-16-
dc.identifier.citationCancers 2023; 15(2)en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/32005-
dc.description.abstractThe p21 Activated Kinases (PAKs) are serine threonine kinases and play important roles in many biological processes, including cell growth, survival, cytoskeletal organization, migration, and morphology. Recently, PAKs have emerged in the process of liver disorders, including liver cancer, hepatic ischemia-reperfusion injury, hepatitis, and liver fibrosis, owing to their effects in multiple signaling pathways in various cell types. Activation of PAKs promotes liver cancer growth and metastasis and contributes to the resistance of liver cancer to radiotherapy and chemotherapy, leading to poor survival of patients. PAKs also play important roles in the development and progression of hepatitis and other pathological processes of the liver such as fibrosis and ischemia-reperfusion injury. In this review, we have summarized the currently available studies about the role of PAKs in liver disorders and the mechanisms involved, and further explored the potential therapeutic application of PAK inhibitors in liver disorders, with the aim to provide a comprehensive overview on current progress and perspectives of PAKs in liver disorders.en_US
dc.language.isoeng-
dc.subjecthepatic ischemia-reperfusion injuryen_US
dc.subjecthepatitisen_US
dc.subjectliver canceren_US
dc.subjectliver fibrosisen_US
dc.subjectp21 Activated Kinaseen_US
dc.subjectsmall molecular inhibitorsen_US
dc.titleP-21 Activated Kinases in Liver Disorders.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleCancersen_US
dc.identifier.affiliationKey Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.en_US
dc.identifier.affiliationKey Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.en_US
dc.identifier.affiliationKey Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.en_US
dc.identifier.affiliationZhejiang University School of Medicine, Hangzhou 310058, China.en_US
dc.identifier.affiliationSurgery (University of Melbourne)en_US
dc.identifier.doi10.3390/cancers15020551en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0001-5930-1877en_US
dc.identifier.orcid0000-0002-2761-2811en_US
dc.identifier.orcid0000-0002-2342-8750en_US
dc.identifier.pubmedid36672500-
dc.description.volume15-
dc.description.issue2-
local.name.researcherHe, Hong
item.grantfulltextnone-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
crisitem.author.deptSurgery (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

36
checked on Nov 19, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.